Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 196 JPY 0.51% Market Closed
Market Cap: 17.7B JPY
Have any thoughts about
Healios KK?
Write Note

Healios KK
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Healios KK
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Healios KK
TSE:4593
Common Shares Outstanding
ÂĄ90.1m
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Common Shares Outstanding
ÂĄ50.1m
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
4%
PeptiDream Inc
TSE:4587
Common Shares Outstanding
ÂĄ129.6m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
2%
Takara Bio Inc
TSE:4974
Common Shares Outstanding
ÂĄ120.4m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Pharma Foods International Co Ltd
TSE:2929
Common Shares Outstanding
ÂĄ28.1m
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
0%
C
Cuorips Inc
TSE:4894
Common Shares Outstanding
ÂĄ8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Healios KK
Glance View

Market Cap
17.7B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
142.89 JPY
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Healios KK's Common Shares Outstanding?
Common Shares Outstanding
90.1m JPY

Based on the financial report for Sep 30, 2024, Healios KK's Common Shares Outstanding amounts to 90.1m JPY.

What is Healios KK's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
12%

Over the last year, the Common Shares Outstanding growth was 21%. The average annual Common Shares Outstanding growth rates for Healios KK have been 18% over the past three years , 12% over the past five years .

Back to Top